Sphera Funds Management LTD. Acquires New Holdings in Tenax Therapeutics, Inc. (NASDAQ:TENX)

Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 29,166 shares of the specialty pharmaceutical company’s stock, valued at approximately $101,000. Sphera Funds Management LTD. owned 0.86% of Tenax Therapeutics at the end of the most recent quarter.

Separately, Vestal Point Capital LP acquired a new stake in Tenax Therapeutics during the 3rd quarter worth about $288,000. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Price Performance

Shares of NASDAQ TENX opened at $5.89 on Friday. The business has a fifty day moving average of $4.46 and a two-hundred day moving average of $3.86. Tenax Therapeutics, Inc. has a 52-week low of $2.77 and a 52-week high of $27.55.

Analyst Ratings Changes

Several analysts have issued reports on the company. William Blair assumed coverage on Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. Guggenheim started coverage on Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. StockNews.com started coverage on Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating on the stock. Finally, Leerink Partners initiated coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.